Product Information
CRESEMBA 186 MG CAPSULE is a brand product labeled by Astellas Pharma US, Inc., priced at $113.9982 per EA under NDC 00469052002. Its NADAC has been published 198 times since Dec 21, 2022.
FDA first approved this application on Mar 6, 2015.
Strength
100 mg/1
Manufacturer
Astellas Pharma US, Inc.NDC
00469052002
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ISAVUCONAZONIUM SULFATEApproval Type
New Drug (NDA)
FDA Application
NDA207500FDA Approved
3/6/2015
On Market Since
11/4/2015
Pharmacological Classes
Price Statistics
The NADAC for CRESEMBA 186 MG CAPSULE has been published 198 times since Dec 21, 2022, and over the history we have for it it has risen 17.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $113.9982 per EA |
|---|---|
| All-time high | $114.1261 (Jun 10, 2026) |
| All-time low | $96.8884 (Dec 21, 2022) |
| 52-week high | $114.1261 |
| 52-week low | $110.7541 |
| Median price | $108.1229 |
| Average price | $108.0338 |
| Largest weekly change | +6.0% (Jan 25, 2023) |
| Weeks tracked | 198 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the isavuconazonium sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Astellas Pharma US, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
isavuconazonium sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Azole Antifungal class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CRESEMBA 186 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CRESEMBA 186 MG CAPSULE, manufactured by Astellas Pharma US, Inc., is $113.9982 per EA (NDC 00469052002), effective Sep 30, 2026.
How has the price of CRESEMBA 186 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CRESEMBA 186 MG CAPSULE has risen 17.7%. It has been tracked across 198 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for CRESEMBA 186 MG CAPSULE?
Since Dec 21, 2022, the NADAC for CRESEMBA 186 MG CAPSULE has ranged from a low of $96.8884 (Dec 21, 2022) to a high of $114.1261 (Jun 10, 2026), with a median of $108.1229 per EA.
Are there cheaper alternatives to CRESEMBA 186 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of CRESEMBA 186 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CRESEMBA 186 MG CAPSULE?
CRESEMBA 186 MG CAPSULE (NDC 00469052002) is labeled by Astellas Pharma US, Inc., and CMS classifies it as a brand product.